This event is exclusively for registered medical professionals based in New Zealand.
Please join us for a discussion on the introduction of Herzuma® in New Zealand and what the transition means for patients requiring trastuzumab treatment.
Chaired by Dr Kate Gregory, Professor Justin Stebbing and Dr Daisy Wing-san Mak will cover the latest evidence and in-use stability data of Herzuma® and discuss what the introduction and transition to Herzuma® means for you and your patients.
From 1 June 2024, every patient who requires trastuzumab will have needed to be transitioned to Herzuma®. This is now the only funded trastuzumab available to treat New Zealand patients with HER2-positive early and metastatic breast cancer, gastric, gastro-oesophageal junction, and oesophageal cancer.
5
Demonstrate a framework for assessing menopausal symptom severity and for providing advice to women on options for optimal management.
1
Stay Informed: Get the latest insights from a global expert in trastuzumab
3
Summarise current evidence regarding the efficacy and safety of MHT and non-hormonal therapies for menopause symptoms.
2
Shape the Future: Learn how Herzuma® and biosimilars will shape cancer treatment in New Zealand.
4
Consultant Medical Oncologist
© Praxhub 2024, all rights reserved.
New Zealand Standard Time: 7:00pm
Aukland/Wellington (GMT +12)
Australian Eastern Standard Time: 5:00pm
Melbourne/Canberra/Sydney/Hobart (GMT+10)
Norfolk Island Daylight Time: 6:00pm
(GMT+12)
Australian Central Daylight Time: 4:30pm
Adelaide (GMT+10.30)
Australian Western Standard Time: 3:00pm
Perth (GMT+8)
Christmas Island Time: 2:00pm
(GMT+7)
Timezones
SCROLL
Registering for Praxhub webinars is now even easier!
Are you new to Praxhub? Welcome!
One-click registration for Praxhub members: